Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held … and RNAi platforms and authored more than 90 peer-reviewed scientific publications, reviews and book chapters and is the … Dr. Maier is a current member of ProQR’s ScientificAdvisoryBoard. “We’re very pleased to nominate Martin Maier …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi